161 related articles for article (PubMed ID: 28854096)
1. Targeting the Colorectal Cancer Stem Cell.
Medema JP
N Engl J Med; 2017 Aug; 377(9):888-890. PubMed ID: 28854096
[No Abstract] [Full Text] [Related]
2. Targeting the SPHK1/HIF1 Pathway to Inhibit Colorectal Cancer Stem Cells Niche.
Khoei SG; Sadeghi H; Dermani FK
J Gastrointest Cancer; 2020 Jun; 51(2):716-717. PubMed ID: 31093935
[No Abstract] [Full Text] [Related]
3. Biomarker targeting of colorectal cancer stem cells.
Caparosa EM; Stem J; Snook AE; Waldman SA
Biomark Med; 2019 Aug; 13(11):891-894. PubMed ID: 31385523
[No Abstract] [Full Text] [Related]
4. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel Molecules Targeting Cancer Stem Cells.
Benoit YD
Methods Mol Biol; 2018; 1765():333-347. PubMed ID: 29589319
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
Kato J; Futamura M; Kanematsu M; Gaowa S; Mori R; Tanahashi T; Matsuhashi N; Yoshida K
Int J Cancer; 2016 Mar; 138(6):1516-27. PubMed ID: 26437179
[TBL] [Abstract][Full Text] [Related]
7. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
[TBL] [Abstract][Full Text] [Related]
8. Targeting cancer stem cells as therapeutic approach in the treatment of colorectal cancer.
Parizadeh SM; Jafarzadeh-Esfehani R; Hassanian SM; Parizadeh SMR; Vojdani S; Ghandehari M; Ghazaghi A; Khazaei M; Shahidsales S; Rezayi M; Asgharzadeh F; Ghayour-Mobarhan M; Ferns GA; Avan A
Int J Biochem Cell Biol; 2019 May; 110():75-83. PubMed ID: 30818083
[TBL] [Abstract][Full Text] [Related]
9. ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.
Geißler AL; Geißler M; Kottmann D; Lutz L; Fichter CD; Fritsch R; Weddeling B; Makowiec F; Werner M; Lassmann S
Oncotarget; 2017 Mar; 8(10):17164-17190. PubMed ID: 28199979
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells.
Kemper K; Prasetyanti PR; De Lau W; Rodermond H; Clevers H; Medema JP
Stem Cells; 2012 Nov; 30(11):2378-86. PubMed ID: 22969042
[TBL] [Abstract][Full Text] [Related]
11. Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).
Cushman SM; Jiang C; Hatch AJ; Shterev I; Sibley AB; Niedzwiecki D; Venook AP; Owzar K; Hurwitz HI; Nixon AB
Clin Cancer Res; 2015 Mar; 21(5):1078-86. PubMed ID: 25520391
[TBL] [Abstract][Full Text] [Related]
12. Colorectal cancer stem cells as biomarkers: where it all starts?
Avital I; Summers TA; Steele SR; Waldman S; Nissan A; Bilchik AJ; Protic M; Man YG; Brücher BL; Stojadinovic A
J Surg Oncol; 2013 Jun; 107(8):791-3. PubMed ID: 23512573
[No Abstract] [Full Text] [Related]
13. Oncogenic KRAS activates an embryonic stem cell-like program in human colon cancer initiation.
Le Rolle AF; Chiu TK; Zeng Z; Shia J; Weiser MR; Paty PB; Chiu VK
Oncotarget; 2016 Jan; 7(3):2159-74. PubMed ID: 26744320
[TBL] [Abstract][Full Text] [Related]
14. Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways.
Kahlert UD; Mooney SM; Natsumeda M; Steiger HJ; Maciaczyk J
Int J Cancer; 2017 Jan; 140(1):10-22. PubMed ID: 27389307
[TBL] [Abstract][Full Text] [Related]
15. Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer.
Song L; Li Y; He B; Gong Y
Clin Colorectal Cancer; 2015 Sep; 14(3):133-45. PubMed ID: 25799881
[TBL] [Abstract][Full Text] [Related]
16. High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour-initiating properties of colon cancer stem cells.
Puglisi MA; Cenciarelli C; Tesori V; Cappellari M; Martini M; Di Francesco AM; Giorda E; Carsetti R; Ricci-Vitiani L; Gasbarrini A
J Pathol; 2015 Aug; 236(4):479-90. PubMed ID: 25875314
[TBL] [Abstract][Full Text] [Related]
17. Molecular Triage Trials in Colorectal Cancer.
O'Hara MH; Hamilton SR; O'Dwyer PJ
Cancer J; 2016; 22(3):218-22. PubMed ID: 27341602
[TBL] [Abstract][Full Text] [Related]
18. Cancer Stem Cell-Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance.
De Angelis ML; Zeuner A; Policicchio E; Russo G; Bruselles A; Signore M; Vitale S; De Luca G; Pilozzi E; Boe A; Stassi G; Ricci-Vitiani L; Amoreo CA; Pagliuca A; Francescangeli F; Tartaglia M; De Maria R; Baiocchi M
Stem Cells Transl Med; 2016 Apr; 5(4):511-23. PubMed ID: 26956206
[TBL] [Abstract][Full Text] [Related]
19. Thioridazine elicits potent antitumor effects in colorectal cancer stem cells.
Zhang C; Gong P; Liu P; Zhou N; Zhou Y; Wang Y
Oncol Rep; 2017 Feb; 37(2):1168-1174. PubMed ID: 28000884
[TBL] [Abstract][Full Text] [Related]
20. Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function.
Storm EE; Durinck S; de Sousa e Melo F; Tremayne J; Kljavin N; Tan C; Ye X; Chiu C; Pham T; Hongo JA; Bainbridge T; Firestein R; Blackwood E; Metcalfe C; Stawiski EW; Yauch RL; Wu Y; de Sauvage FJ
Nature; 2016 Jan; 529(7584):97-100. PubMed ID: 26700806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
